Nuvalent (NASDAQ:NUVL) Insider Deborah Ann Miller Sells 700 Shares of Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Deborah Ann Miller sold 700 shares of Nuvalent stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $109.84, for a total transaction of $76,888.00. Following the completion of the transaction, the insider directly owned 59,634 shares of the company’s stock, valued at $6,550,198.56. The trade was a 1.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Deborah Ann Miller also recently made the following trade(s):

• On Thursday, January 22nd, Deborah Ann Miller sold 14,300 shares of Nuvalent stock. The shares were sold at an average price of $110.16, for a total value of $1,575,288.00.
• On Tuesday, January 6th, Deborah Ann Miller sold 2,589 shares of Nuvalent stock. The shares were sold at an average price of $97.16, for a total value of $251,547.24.
• On Monday, January 5th, Deborah Ann Miller sold 4,363 shares of Nuvalent stock. The stock was sold at an average price of $97.32, for a total value of $424,607.16.
• On Monday, November 17th, Deborah Ann Miller sold 24,200 shares of Nuvalent stock. The shares were sold at an average price of $105.50, for a total value of $2,553,100.00.
• On Thursday, October 30th, Deborah Ann Miller sold 21,800 shares of Nuvalent stock. The shares were sold at an average price of $103.16, for a total value of $2,248,888.00.

Nuvalent Price Performance

Shares of NUVL stock opened at $106.44 on Friday. Nuvalent, Inc. has a 1-year low of $55.53 and a 1-year high of $113.01. The company has a market cap of $7.74 billion, a price-to-earnings ratio of -20.01 and a beta of 1.32. The stock has a 50 day simple moving average of $105.12 and a 200-day simple moving average of $91.07.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same period in the prior year, the firm earned ($1.28) EPS. Analysts anticipate that Nuvalent, Inc. will post -3.86 earnings per share for the current fiscal year.

Institutional Trading of Nuvalent

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its position in shares of Nuvalent by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after acquiring an additional 108 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Nuvalent during the third quarter worth about $38,000. Eastern Bank purchased a new position in Nuvalent during the third quarter worth about $52,000. Persistent Asset Partners Ltd acquired a new position in Nuvalent in the 2nd quarter valued at about $88,000. Finally, Farther Finance Advisors LLC grew its stake in shares of Nuvalent by 9,230.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock valued at $93,000 after buying an additional 1,200 shares during the period. 97.26% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on NUVL. Piper Sandler upped their price target on shares of Nuvalent from $112.00 to $128.00 and gave the stock an “overweight” rating in a research report on Monday, October 27th. Guggenheim increased their target price on Nuvalent from $125.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvalent in a research report on Thursday. JPMorgan Chase & Co. dropped their price target on Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. Finally, Cantor Fitzgerald started coverage on Nuvalent in a research note on Wednesday, October 15th. They issued an “overweight” rating and a $135.00 price objective for the company. Fifteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $138.33.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.